Alnylam (ALNY)
Biotech
Close on Nov 5, 2026 (from our latest article): $156.66
- Market value
- $21.0Bat the Nov 5 close
- Revenue growth
- +56%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 16%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $2.6Bat Sep 30, 2026
- Worst fall since listing
- −83.6%Oct 9, 2007 to Oct 3, 2011; back to that high in Jul 2013
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
Alnylam spent years as a loss-making developer of RNAi drugs for rare diseases, until Amvuttra’s expansion into TTR heart disease, after a 2024 trial and a 2025 approval, drove growth and its first annual profit in 2025, helped by a $300M Roche milestone.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 5, 2026
Our View Opinion
Alnylam is now a profitable one-drug company: Amvuttra, its heart and nerve drug for transthyretin (TTR) amyloidosis, brings in nearly 80% of revenue, and the stock has fallen about 63% in a year as the heart launch has grown more slowly than promised; in October management said it isn't satisfied with demand.
- Median value, end-2030
- $370P10–P90 $250–$540
- Chance of beating the hurdle
- 95%
- Implied end-2030 multiple
- 5.1× 2031 salesP25–P75 4.2–6.1× · today 3.1×
Biggest risk: Our model's central downside case is a plateau, not a collapse, though more severe outcomes remain possible: Amvuttra settles as a second-line or add-on drug while cheap stabilizers keep first-line patients, and the company keeps growing profitably but slowly after 2027.
Nov 5, 2026 · our analysis, not investment advice
More of our coverage that names Alnylam
Long-term fundamentals
Annual results for Alnylam, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $101M in FY2009 to $3.7B in FY2025.
Free cash flow was positive in 2 of the 17 years shown; FY2025: $465M.
Margins
Operating margin was 14% in FY2025, vs −168% in FY2020.
Diluted share count
The diluted share count rose 17% from FY2020 to FY2025, to 135M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.7B | — | 14% | $314M | $524M | $59M | $465M |
| FY2024 | $2.2B | — | −8% | −$278M | −$8M | $34M | −$43M |
| FY2023 | $1.8B | — | −15% | −$440M | $104M | $62M | $42M |
| FY2022 | $1.0B | — | −76% | −$1.1B | −$541M | $72M | −$613M |
| FY2021 | $844M | — | −84% | −$853M | −$642M | $76M | −$718M |
| FY2020 | $493M | — | −168% | −$858M | −$615M | $70M | −$685M |
| FY2019 | $220M | — | −427% | −$886M | −$278M | $140M | −$419M |
| FY2018 | $75M | — | −1088% | −$761M | −$563M | $127M | −$690M |
| FY2017 | $90M | — | −556% | −$491M | −$383M | $104M | −$487M |
| FY2016 | $47M | — | −900% | −$410M | −$308M | $65M | −$372M |
| FY2015 | — | — | — | −$290M | −$189M | $13M | −$202M |
| FY2014 | — | — | — | −$360M | −$166M | $9M | −$175M |
| FY2013 | — | — | — | −$89M | −$69M | $4M | −$73M |
| FY2012 | — | — | — | −$106M | −$116M | $8M | −$124M |
| FY2011 | — | — | — | −$58M | −$87M | $1M | −$88M |
| FY2010 | $100M | — | −44% | −$44M | −$84M | $5M | −$89M |
| FY2009 | $101M | — | −48% | −$48M | −$72M | $5M | −$77M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 135M | $2.9B | $1.0B | $348M | — | — |
| FY2024 | 128M | $2.7B | $1.0B | $272M | — | — |
| FY2023 | 125M | $2.4B | $1.0B | $222M | — | — |
| FY2022 | 122M | $2.2B | $1.0B | $231M | — | — |
| FY2021 | 118M | $2.4B | $676M | $166M | — | — |
| FY2020 | 115M | $1.8B | $191M | $140M | — | — |
| FY2019 | 109M | $1.5B | $0 | $175M | — | — |
| FY2018 | — | $1.1B | $30M | $158M | — | — |
| FY2017 | — | $1.7B | $30M | $93M | — | — |
| FY2016 | — | $943M | $150M | $76M | — | — |
| FY2015 | — | $1.3B | — | $46M | — | — |
| FY2014 | — | $882M | — | $33M | — | — |
| FY2013 | — | $350M | — | $21M | — | — |
| FY2012 | — | $226M | — | $12M | — | — |
| FY2011 | — | $146M | — | $17M | — | — |
| FY2010 | — | $233M | — | $19M | — | — |
| FY2009 | — | $281M | — | $20M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Oct 30, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | ALNY | S&P 500 |
|---|---|---|
| 2019 | +58.0% | +31.5% |
| 2020 | +12.8% | +18.4% |
| 2021 | +30.5% | +28.7% |
| 2022 | +40.1% | −18.1% |
| 2023 | −19.5% | +26.3% |
| 2024 | +22.9% | +25.0% |
| 2025 | +69.0% | +17.9% |
| 2026 to date | −62.8% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- GMAB Genmab Up 28.3%
- MDGL Madrigal Down 8.1%
- TGTX TG Therapeutics Up 5.9%
- CORT Corcept Therapeutics Down 20.1%
- KRYS Krystal Down 11%
- ARWR Arrowhead Down 15.3%
Show all 17
- MRNA Moderna Down 17.6%
- IOVA Iovance Down 35.4%
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- VKTX Viking Therapeutics
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- ORIC ORIC Pharmaceuticals Down 32%
Questions about Alnylam
- How does Alnylam make money?
- Alnylam sells RNA interference (RNAi) medicines, which reduce production of selected disease-causing proteins. In 2025 Amvuttra, for transthyretin (TTR) amyloidosis, was 62% of its $3.71B revenue. The rest came from older drugs (Onpattro, Givlaari and Oxlumo), collaboration payments (mainly Roche, including a one-time $300M milestone) and royalties (mainly Novartis's Leqvio). More in the Long View →
- What drives Alnylam's growth?
- Amvuttra's expansion into TTR amyloidosis affecting the heart, following US approval in 2025, drove growth. Alnylam reported its first annual GAAP profit in 2025, helped by a one-time $300M Roche milestone. More in the Long View →
- How dependent is Alnylam on Amvuttra?
- Amvuttra accounted for 62% of Alnylam's total revenue in 2025. Alnylam pays Sanofi tiered royalties of 15–30% on Amvuttra sales. More in the Long View →
- What are the main risks to Alnylam's business?
- Alnylam identifies insurer reimbursement as a sales risk. Amvuttra is paid for mainly under Medicare Part B, a meaningful portion of its US units is bought under the 340B discount programme, and certain Medicare Advantage plans now require patients to try another drug first. Its distributor concentration creates credit and distribution exposure, and it shares Amvuttra's economics with Sanofi and Blackstone. More in the Long View →
- What could follow Amvuttra?
- Alnylam is developing nucresiran, an investigational successor for TTR amyloidosis that carries no Sanofi royalty. It still requires successful clinical development and regulatory approval. More in the Long View →
- What's coming up for Alnylam's pipeline in the next 12 months?
- Alnylam expects Phase 2 ALN-6400 data in hereditary hemorrhagic telangiectasia and Phase 1 ALN-2232 data in obesity and weight management with its fourth quarter and full year 2026 earnings call in February 2027. It plans a pivotal brezosiran study in 2027, pending regulatory alignment. Alnylam says Regeneron's cemdisiran has a PDUFA target action date in November 2026; if approved, Alnylam is eligible for royalties. As of Nov 5, 2026 More in the Long View →
Disclosure: one or more of our editors own shares of Alnylam (ALNY) as a long-term investment.